MediWound Ltd. (NASDAQ:MDWD)’s share price traded up 16% on Wednesday . The company traded as high as $7.50 and last traded at $7.39, with a volume of 122,275 shares. The stock had previously closed at $6.37.

A number of equities analysts have weighed in on the company. Brean Capital restated a “buy” rating on shares of MediWound in a research note on Saturday, April 23rd. Wells Fargo & Co. assumed coverage on MediWound in a research note on Wednesday. They issued an “outperform” rating and a $14.00 target price on the stock. Jefferies Group decreased their target price on MediWound from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, July 29th. Finally, Zacks Investment Research lowered MediWound from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. MediWound presently has a consensus rating of “Buy” and an average target price of $13.63.

The stock’s market cap is $175.02 million. The company’s 50-day moving average is $7.49 and its 200 day moving average is $7.67.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.11. During the same period in the prior year, the firm earned ($0.19) earnings per share. The company earned $3.36 million during the quarter, compared to the consensus estimate of $0.45 million. MediWound’s revenue for the quarter was up 115.8% compared to the same quarter last year. Equities research analysts anticipate that MediWound Ltd. will post ($1.03) earnings per share for the current fiscal year.

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.